Patient characteristics of tuberculosis and nontuberculous mycobacterial (NTM) cases* compared with non-cases among patients with anti-TNF use during the study time-period
| Uninfected (n=8384) # (%) | TB (n=16) # (%) | OR§(95% CI) | NTM (n=18) # (%) | OR¶ (95% CI) | |
|---|---|---|---|---|---|
| Sex (female) | 5374 (64) | 13 (81) | 2.4 (0.7 to 8.5) | 13 (72) | 1.5 (0.5 to 4.1) |
| White† | 5087 (61) | 4 (25) | 0.2 (0.1 to 0.7) | 17 (94) | 11.0 (1.5 to 82.8) |
| English as primary language | 7777 (93) | 13 (81) | 0.3 (0.1 to 1.2) | 17 (94) | 1.3 (0.2 to 10.0) |
| Age, median (range) | 50 (2–110) | 57.5 (31–77) | 1.02 (1.0 to 1.1) | 68 (49–81) | 1.1 (1.0 to 1.1) |
| Body mass index, median (range) | 27 (23–41) | 25 (23–30) | 0.8 (0.7 to 1.01) | 24 (23–33) | 0.9 (0.8 to 1.0) |
| Chronic renal disease† | 547 (7) | 4 (25) | 4.8 (1.5 to 14.9) | N/A | N/A |
| Diabetes mellitus† | 1367 (16) | 6 (38) | 3.1 (1.1 to 8.5) | N/A | N/A |
| RA | 5060 (60) | 12 (75) | 2.0 (0.6 to 6.1) | 18 (100) | Undefined |
| Crohn's | 760 (9) | 1 (6) | 0.7 (0.1 to 5.1) | 0 (0) | Undefined |
| Ulcerative colitis | 458 (6) | 1 (6) | 1.2 (0.2 to 8.8) | 0 (0) | Undefined |
| AS | 439 (5) | 0 (0) | Undefined | 2 (11) | 2.3 (0.5 to 9.9) |
| Psoriasis | 2347 (28) | 3 (19) | 0.6 (0.2 to 2.1) | 3 (17) | 0.5 (0.1 to 1.8) |
| Death during the study time period† | 367 (4) | 3 (19) | 5.2 (1.0 to 19.1)‡ | 7 (39) | 14.4 (4.7 to 40.8)‡ |
| Chronic lung disease† | 2385 (28) | N/A | N/A | 13 (72) | 6.5 (2.3 to 18.4) |
| GERD† | 2746 (33) | N/A | N/A | 13 (72) | 5.3 (1.9 to 15.0) |
| Anti-TNF agents used | |||||
| Infliximab | 2778 (33) | 8 (50) | 2.0 (0.8 to 5.4) | 12 (67) | 4.0 (1.5 to 10.8) |
| Etanercept | 5320 (64) | 8 (50) | 0.6 (0.2 to 1.5) | 10 (56) | 0.7 (0.3 to 1.8) |
| Adalimumab | 2331 (28) | 7 (44) | 2.0 (0.8 to 5.4) | 6 (33) | 1.3 (0.5 to 3.5) |
↵* Descriptive characteristics of all TB and NTM cases among our cohort of anti-TNF users, including those in whom disease was diagnosed while not actively exposed to anti-TNF therapy.
↵† p<0.05 for comparison between NTM/TB cases and uninfected anti-TNF users.
↵‡ OR for death.
↵§ OR for comparison between TB cases and non-cases among anti-TNF users.
↵¶ OR for comparison between NTM cases and non-cases among anti-TNF users.
AS, ankylosing spondylitis; GERD, gastro-esophageal reflux disease; N/A denotes ‘not measured’; RA, rheumatoid arthritis; TNF, tumour necrosis factor.